Oxurion To Present at Upcoming Scientific and Investor Conferences
August 24 2022 - 1:00PM
Oxurion To Present at Upcoming Scientific and Investor Conferences
Leuven, BELGIUM, Boston, MA, US
– August
24, 2022
– Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical
company developing next generation standard of care ophthalmic
therapies, with clinical stage assets in vascular retinal
disorders, announced that it will participate in three upcoming
conferences.
22nd EURETINA
Congress – Hamburg,
GermanyDate: Friday, September 2, 2022 | 12:15 p.m.
CET
Title: “Results of Part A of KALAHARI, a Phase 2
Trial of THR-149, a plasma kallikrein (pKal) inhibitor, for the
treatment of diabetic macular edema (DME)” presented by Timothy L.
Jackson, MD.
H.C. Wainwright & Co.,
24th Annual
Global Investment Conference
– New York, NY & Virtual Date: Monday,
September 12, 2022 | 7:00 a.m. ET Tom Graney, CEO of Oxurion, will
deliver a virtual presentation and is available for one-on-one
meetings.
KBC Securities Life Sciences Conference
– Virtual Date: Friday, September 16, 2022 | 11
a.m. ET Tom Graney, CEO of Oxurion, will deliver a virtual
presentation and is available for one-on-one meetings.
The presentations will be available in the “Investors” section
of the Company’s website.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michael DillenChief Business
OfficerTel: +32 479 783583michael.dillen@oxurion.com |
USConway CommunicationsBeth
Kurthbkurth@conwaycommsir.com ICR WestwickeChristopher
BrinzeyTel: +1 617 835 9304Chris.Brinzey@westwicke.com |
- OXUR September Conferences 2022.0824
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxurion Nv (LSE:0G99)
Historical Stock Chart
From Sep 2023 to Sep 2024